Inventia Life Science | The Culture Newsletter
Advancing Oncology Research with More Predictive Models |  
Welcome to the March edition of The Culture.

As momentum continues to build around human-relevant models, the focus is shifting from concept to application. Across oncology research in particular, scalable 3D systems are playing an increasingly important role in generating more predictive, biologically relevant insight.

This month, we highlight new research, an on-demand oncology webinar, and upcoming opportunities to connect with the Inventia team at AACR 2026, including a preview of new workflow innovations.

We also take a closer look at how New Approach Methodologies (NAMs) are shaping the future of experimental design.

On-Demand Webinar: Next Generation Oncology Drug Discovery with 3D Tumor Models

Developing effective cancer therapies is often limited by the predictive power of traditional preclinical models.

In this on-demand session from Emerging Therapeutic Strategies in Oncology, Sean Porazinski, PhD explores how scalable 3D tumor models can better capture biological complexity while remaining compatible with high-throughput workflows.

Watch the recording →

Inventia Insights: Perspectives on New Approach Methodologies

As momentum builds around human-relevant research models, NAMs are reshaping how scientists approach experimental design and drug development.

New! NAMs News Roundup: The Debate Has Shifted from Adoption to Evidence
Regulatory momentum is accelerating, but the conversation is evolving. This roundup explores how the focus is shifting from whether to adopt NAMs to how to generate robust, decision-grade evidence.
Read the roundup →

New! Why NAM Adoption Stalls: How to Operationalize Decision-Grade Human Models
Building sophisticated models is no longer the barrier. This perspective examines what “decision-grade” really means in practice and why reproducibility, scalability, and workflow integration are critical for adoption.
Explore the insights →

FDA and NIH Are Moving Beyond Animal Models
Recent signals from the FDA and NIH point to a clear shift toward human-relevant research. This article breaks down what these changes mean for experimental design and the future of preclinical models.
Read the story →

New Research: UC2288 decreases the viability and metastatic activity of human Uveal melanoma cells via activating the AMPK/eIF2/ATF4 ER stress axis

A recent study highlights the potential of UC2288 in uveal melanoma, demonstrating anti-tumor effects across in vitro, 3D, and in vivo models.

Using RASTRUM-generated 3D tumor models, the researchers were able to evaluate drug response in a more biologically relevant context, reinforcing the value of incorporating 3D systems into preclinical workflows.

Read the publication →